Altered Antioxidant Status and Increased Lipid Peroxidation in Children with Cystic Fibrosis
Overview
Affiliations
Cystic fibrosis often combines an infectious pathology with a syndrome of malabsorption, both potentially capable of favoring the deleterious effects of reactive oxygen species. This study was a simultaneous evaluation of the main antioxidant systems dependent on micronutrients and of lipid peroxidation products in 27 children with cystic fibrosis and 17 healthy children. Plasma of cystic fibrosis patients showed very low concentrations of beta-carotene (0.30 +/- 0.2 vs 1.63 +/- 0.5 mumol/g cholesterol, P < 0.0001) and a lower activity of selenium-dependent glutathione peroxidase (263.6 +/- 42 vs 296.9 +/- 57 U/L, P = 0.028). In parallel, the higher plasma concentrations of organic hydroperoxides (171.5 +/- 54.4 vs 122.6 +/- 23.3 mumol/L, P = 0.001) and of thiobarbituric acid reactants (2.9 +/- 0.6 vs 2.4 +/- 0.3 mumol/L, P = 0.004) reflected oxidative stress in this pathology. In addition, in these patients the major substrates of lipoperoxidation were significantly lower, whether they be linoleic acid (2.26 +/- 0.8 vs 3.60 +/- 0.9 mmol/L, P < 0.0001) or arachidonic acid (0.55 +/- 0.2 vs 0.74 +/- 0.2 mmol/L, P = 0.006). These results suggested that nutritional deficiencies resulting from malabsorption could considerably amplify disorders related to toxicity of reactive oxygen species. These nutritional deficits could also be aggravated by the destruction of antioxidant compounds by the inflammatory process.
Bennemann G, Moreira E, Pereira L, de Freitas M, de Oliveira D, Ventura J Clin Respir J. 2022; 16(6):475-483.
PMID: 35753706 PMC: 9366585. DOI: 10.1111/crj.13513.
Increased susceptibility of cystic fibrosis airway epithelial cells to ferroptosis.
Maniam P, Essilfie A, Kalimutho M, Ling D, Frazer D, Phipps S Biol Res. 2021; 54(1):38.
PMID: 34903297 PMC: 8670191. DOI: 10.1186/s40659-021-00361-3.
Antioxidant supplementation for lung disease in cystic fibrosis.
Ciofu O, Smith S, Lykkesfeldt J Cochrane Database Syst Rev. 2019; 10:CD007020.
PMID: 31580490 PMC: 6777741. DOI: 10.1002/14651858.CD007020.pub4.
Sommerburg O, De Spirt S, Mattern A, Joachim C, Langhans C, Nesaretnam K Mediators Inflamm. 2015; 2015:817127.
PMID: 25688177 PMC: 4321850. DOI: 10.1155/2015/817127.
Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.
NTimbane T, Comte B, Mailhot G, Berthiaume Y, Poitout V, Prentki M Clin Biochem Rev. 2009; 30(4):153-77.
PMID: 20011209 PMC: 2791770.